Replies to post #103744 on Biotech Values

[AlpineBV_Miller]

...considering HCV and HBV as a package makes no sense in this context.

Sure it does. Sorry if typing fast lead to confusion. Two pools of milestones, one for HBV and one for HCV. Same criteria for both, three markets for each.

Because interferon treatment for HBV is a non-starter for most hepatologists and is a highly questionable proposition from a business standpoint.

Eh?

http://www.hepb.org/patients/treatment_algorithm_summary.htm
http://pharmalicensing.com/public/news/viewNewsML/873/New_Pegasys_Data_Show_Hepatitis_B_Patients_Achieve_Highly_Positive_Treatment_Response_That_Comes_as_Close_to_a_Cure_as_Possible

Interferon for HBV is a blockbuster indication worldwide.